The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile
Open accessAbstract
Reboxetine is the first commercially available norepinephrine reuptake inhibitor developed specifically as a first line therapy for major depressive disorder.In vitro and in vivo pharmacological studies indicated that reboxetine methanesulphonate has high affinity and selectivity for the human norepinephrine transporter over the serotonin and dopamine transporters. Pharmacological specificity is further demonstrated by the absence of affinity for 45 transmitter receptors and CNS targets. Pharmacokinetic studies demonstrated that reboxetine is suitable for twice daily administration (8–10 mg/day) and that it exhibits minimal drug‐drug interactions. The starting dose of reboxetine should be reduced in the elderly, in patients with renal or hepatic impairment, or in patients receiving potent CYP3A inhibitors. A total of 20 phase II/III clinical studies comprising placebo‐controlled, active comparator‐controlled and open‐label uncontrolled studies in both short‐term and long‐term treatment of major depression have been conducted. In the treatment of major depression, reboxetine was superior to placebo in 5 of 12 short‐ or long‐term placebo‐controlled studies and was comparable in efficacy to active comparators in 3 out of 3 active‐controlled studies. Unlike conventional tricyclic antidepressants (TCAs), reboxetine had only minimal sedative and cardiovascular liabilities, probably due to increased pharmacological specificity of reboxetine as compared with TCAs. Unlike serotonin reuptake inhibitors, this selective and specific norepinephrine reuptake inhibitor demonstrated a distinct side‐effect profile with diminishing sexual dysfunction and GI side effects. The availability of this agent has afforded patients suffering from major depressive disorder a new class of agents to combat the debilitating consequence of this psychiatric disease. The demonstrated pharmacological specificity of this compound has provided the psychopharmacology community with a tool to elucidate the role of norepinephrine in brain functions. Testing this agent in different animal models has enabled the exploration of the role of modulation of norepinephrine tone in the therapy of CNS disorders beyond depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 2×
“In contrast, chronic administration of the antipsychotic, haloperidol, failed to induce BDNF expression (89).”
BackgroundGamma (40-100 Hz) oscillation in the hippocampus of the behaving rat
Bragin, A., Jando, G., Nadasdy, Z., Hetke, J., Wise, K., & Buzsaki, G. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-01-00047.1995 · Cited by 1,527
Frontal theta activity in humans increases with memory load in a working memory task
Jensen, O., & Tesche, C. D. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01975.x · Cited by 1,379
Gating of human theta oscillations by a working memory task
Raghavachari, S., Kahana, M. J., Rizzuto, D. S., Caplan, J. B., Kirschen, M. P., Bourgeois, B., Madsen, J. R., & Lisman, J. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03175.2001 · Cited by 792
(1997) · Neuroscience · doi:10.1016/s0306-4522(97)00239-x · Cited by 707
Miller, H. L. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020031005 · Cited by 192
Gross, D. W., & Gotman, J. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00343-7 · Cited by 184
Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients
Ferguson, J. M., Wesnes, K. A., & Schwartz, G. E. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200301000-00002 · Cited by 112
Stress, Synaptic Plasticity, and Psychopathology
Garcia, R. (2002) · Reviews in the Neurosciences · doi:10.1515/revneuro.2002.13.3.195 · Cited by 81
Cited by
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Eyding, D., Lelgemann, M., Grouven, U., Harter, M., Kromp, M., Kaiser, T., Kerekes, M. F., Gerken, M., & Wieseler, B. (2010) · BMJ · doi:10.1136/bmj.c4737 · Cited by 588
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Arylglyoxals in Synthesis of Heterocyclic Compounds
Eftekhari-Sis, B., Zirak, M., & Akbari, A. (2013) · Chemical Reviews · doi:10.1021/cr300176g · Cited by 453
McNaughton, N., Kocsis, B., & Hajós, M. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282ee82e3 · Cited by 187
Self-citation
Metadata
- Authors
- Hajós, M., Fleishaker, J. C., Filipiak‐Reisner, J. K., Brown, M. T., & Wong, E. H. F.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2004-03
- Volume
- 10
- Issue
- 1
- Pages
- 23-44
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W2029799717
- Cited by
- 218
- References
- 11
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile. https://app.cochat.ai/papers/10.1111/j.1527-3458.2004.tb00002.x
- The paper
- Hajós, M., Fleishaker, J. C., Filipiak‐Reisner, J. K., Brown, M. T., & Wong, E. H. F. (2004). The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2004.tb00002.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.